Home » 2014 » October

Monthly Archives: October 2014

Lupin Q2 net profit jumps 54 per cent as US, India sales rise

Lupin Q2 net profit jumps 54 per cent as US, India sales rise Generic drugmaker Lupin has reported a 54 per cent jump in second-quarter profit beating analysts estimates, helped by robust sales in its domestic business and the United States, its largest market. Lupin, India’s second-largest drugmaker by market value, posted a net profit of Rs 6.3 billion ($102.7 ... Read More »

Natco Pharma’s US partner gets FDA nod for wakefulness tablets

Natco Pharma’s US partner gets FDA nod for wakefulness tablets NEW DELHI: Natco Pharma’s marketing partner in US, Breckenridge Pharmaceutical Inc, has received a tentative approval from the US health regulator for its generic Armodafinil tablets used for improving wakefulness in adults. Breckenridge Pharmaceutical Inc has received tentative approval from the United States Food and Drug Administration (USFDA) for Armodafinil ... Read More »

BioReliance launches advanced in-vitro ADME and toxicology services designed to improve drug safety and efficacy

BioReliance launches advanced in-vitro ADME and toxicology services designed to improve drug safety and efficacy BioReliance, Sigma-Aldrich Corporation’s biologics and early-development services business under SAFC Commercial, has introduced select in vitro ADME (absorption, distribution, metabolism and excretion) and toxicology testing services for pharmaceutical, chemical and industrial consumer products to its service offering. The broad set of highly predictive assays use ... Read More »

Pharma patent regime may get stricter, say experts

Pharma patent regime may get stricter, say experts In order to boost dollar inflows in pharma sector and establish stronger IPR regime, govt may affect patent amendments The joint statement issued on September 30 by the US and India to establish an annual high-level Intellectual Property (IP) working group has inevitably led to a debate on whether the governmentwould bow ... Read More »

New data on the global economic impact and burden of preventable blindness and vision impairment

New data on the global economic impact and burden of preventable blindness and vision impairment To highlight the critical need for access to eye care and regular eye examinations, Novartis and its eye care division, Alcon, are introducing new data on World Sight Day, highlighting the economic impact and burden that blindness and vision impairment can have on societies and ... Read More »

Aurobindo Pharma becomes fifth most valuable pharma firm

Aurobindo Pharma becomes fifth most valuable pharma firm Aurobindo Pharma has surged 21% in the past one week, making it the fifth-most valuable Indian pharma company behind Sun Pharmaceutical Industries, Lupin, Dr Reddy’s Laboratories and Cipla. The rally has seen Aurobindo surpass Ranbaxy Laboratories, Cadila Healthcare, Divi’s Laboratories, GlaxoSmithKline Pharmaceuticals, Glenmark Pharmaceuticals, Ipca Laboratories, Torrent Pharma, Biocon and Sanofi India ... Read More »

BIGTheme.net • Free Website Templates - Downlaod Full Themes
Social Media Auto Publish Powered By : XYZScripts.com